Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR^L858R/T790M mutation

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Zhou C, Yao LD. Strategies to improve outcomes of patients with EGRF-mutant non-small cell lung cancer: review of the literature. J Thorac Oncol. 2016;11:174–186. doi:10.1016/j.jtho.2015.10.00226845114
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6:863–873. doi:10.1016/S2213-2600(18)30277-730150014
   PubMed Web of Science ®Google Scholar
• Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36:2702–2709. doi:10.1200/JCO.2018.77.936330059262
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–640. doi:10.1056/NEJMoa161267427959700
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Conway EM, Pikor LA, Kung SH, et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193:116–130. doi:10.1164/rccm.201508-1545CI26583808
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Herbst RS. Nivolumab and pembrolizumab for non-small cell lung cancer. Clin Cancer Res. 2016;22:3713–3717. doi:10.1158/1078-0432.CCR-16-019027252413
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L, Paradigm A. Shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313–326. doi:10.1016/j.cell.2018.07.04930290139
   PubMed Web of Science ®Google Scholar
• Yang M, McKay D, Pollard JW. diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018;78:5492–5503. doi:10.1158/0008-5472.CAN-18-136730206177
   PubMed Web of Science ®Google Scholar
• Hume DA. The many alternative faces of macrophage activation. Front Immunol. 2015;6:370. doi:10.3389/fimmu.2015.0037026257737
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12:1–4. doi:10.1038/cmi.2014.8325220733
   PubMed Web of Science ®Google Scholar
• Costa da Silva M, Breckwoldt MO, Vinchi F, et al. Iron induces anti-tumor activity in tumor-associated macrophages. Front Immunol. 2017;8:1479.29167669
   PubMed Web of Science ®Google Scholar
• Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9:729–737.12576442
   PubMed Web of Science ®Google Scholar
• Chung FT, Lee KY, Wang CW, et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer. 2012;131:E227–35. doi:10.1002/ijc.2759222174092
   PubMedGoogle Scholar
• Zhang B, Zhang Y, Zhao J, et al. M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Med Oncol. 2014;31:127. doi:10.1007/s12032-014-0374-025034365
   PubMedGoogle Scholar
• Tariq M, Zhang JQ, Liang GK, et al. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017;38:1501–1511. doi:10.1038/aps.2016.8929022575
   PubMed Web of Science ®Google Scholar
• Sneha M, Sundaram NM. Preparation and characterization of an iron oxide-hydroxyapatite nanocomposite for potential bone cancer therapy. Int J Nanomed. 2015;10:99–106.
   PubMedGoogle Scholar
• Johnson B, Toland B, Chokshi R, et al. Magnetically responsive paclitaxel-loaded biodegradable nanoparticles for treatment of vascular disease: preparation, characterization and in vitro evaluation of anti-proliferative potential. Curr Drug Deliv. 2010;7:263–273. doi:10.2174/15672011079336062120695837
   PubMedGoogle Scholar
• Klenk C, Gawande R, Uslu L, et al. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 2014;15:275–285. doi:10.1016/S1470-2045(13)70510-224559803
   PubMedGoogle Scholar
• Neuwelt EA, Varallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery. 2007;60:601–611. doi:10.1227/01.NEU.0000255350.71700.3717415196
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang Z, Xue Y, et al. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I: C) promote melanoma regression. Theranostics. 2018;8:6307–6321. doi:10.7150/thno.2974630613299
   PubMed Web of Science ®Google Scholar
• Nikoofal-Sahlabadi S, Matbou Riahi M, Sadri K, et al. Liposomal CpG-ODN: an in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers. Eur J Pharm Sci. 2018;119:159–170. doi:10.1016/j.ejps.2018.04.01829660463
   PubMed Web of Science ®Google Scholar
• He XY, Liu BY, Wu JL, et al. A dual macrophage targeting nanovector for delivery of oligodeoxynucleotides to overcome cancer-associated immunosuppression. ACS Appl Mater Interfaces. 2017;9:42566–42576.29160061
   PubMed Web of Science ®Google Scholar
• Koster BD, van Den Hout M, Sluijter BJR, et al. Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I-II melanoma: data from two randomized phase II trials. Clin Cancer Res. 2017;23:5679–5686. doi:10.1158/1078-0432.CCR-17-094428972083
   PubMed Web of Science ®Google Scholar
• Carpentier A, Metellus P, Ursu R, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol. 2010;12:401–408. doi:10.1093/neuonc/nop04720308317
   PubMed Web of Science ®Google Scholar
• Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol. 2012;746:95–108.22639162
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28:4324–4332. doi:10.1200/JCO.2010.28.979320697067
   PubMed Web of Science ®Google Scholar
• Belani CP, Nemunaitis JJ, Chachoua A, et al. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther. 2013;14:557–563. doi:10.4161/cbt.2459823792641
   PubMed Web of Science ®Google Scholar
• Manegold C, Gravenor D, Woytowitz D, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3979–3986. doi:10.1200/JCO.2007.15.277718711188
   PubMed Web of Science ®Google Scholar
• Chen B, Sun J, Fan F, et al. Ferumoxytol of ultrahigh magnetization produced by hydrocooling and magnetically internal heating co-precipitation. Nanoscale. 2018;10:7369–7376. doi:10.1039/C8NR00736E29644371
   PubMedGoogle Scholar
• Chen B, Li Y, Zhang X, et al. An efficient synthesis of ferumoxytol induced by alternating-current magnetic field. Mater Lett. 2016;170:93–96. doi:10.1016/j.matlet.2016.02.006
   Web of Science ®Google Scholar
• Fulcher D, Wong S. Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory. Immunol Cell Biol. 1999;77:559–564. doi:10.1046/j.1440-1711.1999.00870.x10571678
   PubMed Web of Science ®Google Scholar
• Asquith B, Debacq C, Florins A, et al. Quantifying lymphocyte kinetics in vivo using carboxyfluorescein diacetate succinimidyl ester (CFSE). Proc Biol Sci. 2006;273:1165–1171. doi:10.1098/rspb.2005.343216600897
   PubMedGoogle Scholar
• Vigneron S, Sundermann L, Labbe JC, et al. Cyclin A-cdk1-dependent phosphorylation of bora is the triggering factor promoting mitotic entry. Dev Cell. 2018;45:637–650; e637. doi:10.1016/j.devcel.2018.05.005
   PubMed Web of Science ®Google Scholar
• Zheng G, Yu H. Cyclin a turns on bora to light the path to mitosis. Dev Cell. 2018;45:542–543. doi:10.1016/j.devcel.2018.05.01729870714
   PubMedGoogle Scholar
• Kalimutho M, Sinha D, Jeffery J, et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med. 2018;10:e8566. doi:10.15252/emmm.20170856630108112
   PubMedGoogle Scholar
• Mohamed TMA, Ang YS, Radzinsky E, et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 2018;173:104–116. doi:10.1016/j.cell.2018.02.01429502971
   PubMed Web of Science ®Google Scholar
• Hu J, Zhang H, Cao M, et al. Auranofin enhances ibrutinib‘s anticancer activity in EGFR-mutant lung adenocarcinoma. Mol Cancer Ther. 2018;17:2156–2163. doi:10.1158/1535-7163.MCT-17-117330065099
   PubMedGoogle Scholar
• Temraz S, Shamseddine A, Mukherji D, et al. Ki67 and P53 in relation to disease progression in metastatic pancreatic cancer: a single institution analysis. Pathol Oncol Res. 2018. doi:10.1007/s12253-018-0464-y
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–1061. doi:10.1158/2159-8290.CD-13-064624893891
   PubMed Web of Science ®Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560–562. doi:10.1038/nm.385425939061
   PubMed Web of Science ®Google Scholar
• Nie K, Zhang Z, Zhang C, et al. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018;121:5–11. doi:10.1016/j.lungcan.2018.04.01229858027
   PubMed Web of Science ®Google Scholar
• Hata A, Katakami N, Kaji R, et al. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: multicenter, single-arm, phase 2 trial (ABC Study). Cancer. 2018;124:3830–3838. doi:10.1002/cncr.3167830192383
   PubMedGoogle Scholar
• Tozuka T, Seike M, Minegishi Y, et al. Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. Onco Targets Ther. 2018;11:5601–5605. doi:10.2147/OTT.S16859830237726
   PubMed Web of Science ®Google Scholar
• Futterer S, Andrusenko I, Kolb U, et al. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal. 2013;86:151–160. doi:10.1016/j.jpba.2013.07.01323998966
   PubMed Web of Science ®Google Scholar
• Lu M, Cohen MH, Rieves D, et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85:315–319.20201089
   PubMed Web of Science ®Google Scholar
• Adeegbe DO, Liu S, Hattersley MM, et al. BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer. Cancer Immunol Res. 2018;6:1234–1245. doi:10.1158/2326-6066.CIR-18-007730087114
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–2229. doi:10.1056/NEJMoa180906430280641
   PubMed Web of Science ®Google Scholar
• Li X, Zhang P, Liu X, et al. Expression of interleukin-12 by adipose-derived mesenchymal stem cells for treatment of lung adenocarcinoma. Thorac Cancer. 2015;6:80–84. doi:10.1111/1759-7714.1215126273339
   PubMedGoogle Scholar
• Yue T, Zheng X, Dou Y, et al. Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy. BMC Cancer. 2016;16:665. doi:10.1186/s12885-016-2701-727549240
   PubMed Web of Science ®Google Scholar
• Zhu J, Xin Y, Liu X, et al. Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-alpha by inhibiting the nuclear factor-small ka, CyrillicB signaling pathway. Exp Ther Med. 2018;15:3345–3351.29545853
   PubMed Web of Science ®Google Scholar
• Harada M, Morimoto K, Kondo T, et al. Quinacrine inhibits ICAM-1 transcription by blocking DNA binding of the NF-kappaB subunit p65 and sensitizes human lung adenocarcinoma A549 cells to TNF-alpha and the fas ligand. Int J Mol Sci. 2017;18(12):e2603. doi:10.3390/ijms1812260329207489
   PubMedGoogle Scholar
• Chen MF, Huang SJ, Huang CC, et al. Saikosaponin d induces cell death through caspase-3-dependent, caspase-3-independent and mitochondrial pathways in mammalian hepatic stellate cells. BMC Cancer. 2016;16:532. doi:10.1186/s12885-016-2599-027461108
   PubMedGoogle Scholar
• Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179:2493–2500. doi:10.4049/jimmunol.179.4.249317675511
   PubMed Web of Science ®Google Scholar
• Manegold C, van Zandwijk N, Szczesna A, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2012;23:72–77. doi:10.1093/annonc/mdr03021464154
   PubMed Web of Science ®Google Scholar
• Gallotta M, Assi H, Degagne E, et al. Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4(+) and CD8(+) T-cell interplay. Cancer Res. 2018;78:4943–4956. doi:10.1158/0008-5472.CAN-18-072929945961
   PubMedGoogle Scholar